Login / Signup

Drugs and diseases: Summary and consensus statements of group 1. The 5th EAO Consensus Conference 2018.

Henning SchliephakeAlberto SiciliaBilal Al NawasNikos DonosReinhard GruberSøren JepsenIva MilinkovicAndrea MombelliJose Manuel NavarroMarc QuirynenIsabella RocchiettaMorten SchiødtSøren SchouAlexandra StähliAndreas Stavropoulos
Published in: Clinical oral implants research (2019)
Results and conclusions of the individual reviews of the three topics are presented in the respective papers. Conclusions of the group on strengths and weaknesses of available evidence as well as consensus statements and directions for further research are provided in this study. The following papers were subject to group discussions and formed the basis for the consensus statements: Stähli A, Strauss FJ, Gruber R. () The use of platelet-rich-plasma to enhance the outcomes of implant-related therapies: a systematic review Strauss FJ, Stähli A, Gruber R. (2018) The use of platelet-rich-fibrin to enhance the outcomes of implant-related therapies: a systematic review Mombelli A, Hashim D, Cionca N. () What is the impact of titanium particles and bio-corrosion on implant survival and complications? A critical review Stavropoulos A, Bertl K, Pietschmann P, Pandis N, Morten Schiødt, Klinge B. () The effect of antiresorptive drugs on implant therapy: a systematic review.
Keyphrases
  • platelet rich plasma
  • soft tissue
  • clinical practice
  • type diabetes
  • stem cells
  • drug induced
  • systematic review
  • insulin resistance